|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roder DM: The epidemiology of gastric
cancer. Gastric Cancer. 5 Suppl 1:S5–S11. 2002. View Article : Google Scholar
|
|
3
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and Trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mesner PW Jr, Budihardjo II and Kaufmann
SH: Chemotherapy-induced apoptosis. Adv Pharmacol. 41:461–499.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaufmann SH and Earnshaw WC: Induction of
apoptosis by cancer chemotherapy. Exp Cell Res. 256:42–49. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hannun YA: Apoptosis and the dilemma of
cancer chemotherapy. Blood. 89:1845–1853. 1997.PubMed/NCBI
|
|
7
|
Sharma SV, Lee DY, Li B, Quinlan MP,
Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach
MA, et al: A chromatin-mediated reversible drug-tolerant state in
cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kostova I: Platinum complexes as
anticancer agents. Recent Pat Anticancer Drug Discov. 1:1–22. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma L, Feldstein Teruya J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma L, Reinhardt F, Pan E, Soutschek J,
Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA:
Therapeutic silencing of mir-10b inhibits metastasis in a mouse
mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: Predictors and modifiers of chemo and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martinez I, Gardiner AS, Board KF, Monzon
FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces
the expression of microRNA-218 in cervical carcinoma cells.
Oncogene. 27:2575–2582. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Petrocca F, Visone R, Onelli MR, Shah MH,
Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini
M, et al: E2F1-regulated microRNAs impair TGFbeta-dependent
cell-cycle arrest and apopto-sis in gastric cancer. Cancer Cell.
13:272–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Q, Yang Z, Chen M and Liu Y:
Downregulation of microRNA-196a enhances the sensitivity of
non-small cell lung cancer cells to cisplatin treatment. Int J Mol
Med. 37:1067–1074. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moriyama M, Tsukamoto Y, Fujiwara M, Kondo
G, Nakada C, Baba T, Ishiguro N, Miyazaki A, Nakamura K, Hori N, et
al: Identification of a novelhuman ankyrin-repeated protein
homologous to CARP. Biochem Biophys Res Commun. 285:715–723. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang LL, Wang L, Wang XY, Shang D, Yin SJ,
Sun LL and Ji HB: MicroRNA-218 inhibits the proliferation,
migration, and invasion and promotes apoptosis of gastric cancer
cells by targeting LASP1. Tumour Biol. 37:15241–15252. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu W, Shan X, Wang TS, Shu YQ and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu Y, Xu K and Yagüe E: miR-218 targets
survivin and regulates resistance to chemotherapeutics in breast
cancer. Breast Cancer Res Treat. 151:269–280. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao
H, Gong C, Chen J, Su F, Zhang Y and Song E: Reduced miR-128 in
breast tumor-initiating cells induces chemotherapeutic resistance
via Bmi-1 and ABCC5. Clin Cancer Res. 17:7105–7115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Creevey L, Ryan J, Harvey H, Bray IM,
Meehan M, Khan AR and Stallings RL: MicroRNA-497 increases
apoptosis in MYCN amplified neuroblastoma cells by targeting the
key cell cycle regulator WEE1. Mol Cancer. 12:232013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen DQ, Pan BZ, Huang JY, Zhang K, Cui
SY, De W, Wang R and Chen LB: HDAC 1/4-mediated silencing of
microRNA-200b promotes chemoresistance in human lung adenocarcinoma
cells. Oncotarget. 5:3333–3349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan
FK, Sung JJ and Yu J: MicroRNA-218 inhibits cell cycle progression
and promotes apoptosis in colon cancer by downregulating BMI1
poly-comb ring finger oncogene. Mol Med. 18:1491–1498.
2013.PubMed/NCBI
|
|
33
|
Li J, Ping Z and Ning H: MiR-218 impairs
tumor growth andincreases chemo-sensitivity to cisplatin in
cervical cancer. Int J Mol Sci. 13:16053–16064. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Uesugi A, Kozaki K, Tsuruta T, Furuta M,
Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive
microRNAmiR-218 targets the mTOR component Rictor and inhibits
AKTphosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL
and Yao GL: Reduced expression of circulating microRNA-218 in
gastric cancer and correlation with tumor invasion and prognosis.
World J Gastroenterol. 20:6906–6911. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marusawa H, Matsuzawa S, Welsh K, Zou H,
Armstrong R, Tamm I and Reed JC: HBXIP functions as a cofactor of
survivin in apoptosis suppression. EMBO J. 22:2729–2740. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Singh N, Krishnakumar S, Kanwar RK, Cheung
CH and Kanwar JR: Clinical aspects for survivin: A crucial molecule
for targeting drug-resistant cancers. Drug Discov Today.
20:578–587. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Waligórska-Stachura J, Jankowska A, Waśko
R, Liebert W, Biczysko M, Czarnywojtek A, Baszko-Błaszyk D, Shimek
V and Ruchała M: Survivin-prognostic tumor biomarker in human
neoplasms-review. Ginekol Pol. 83:537–540. 2012.PubMed/NCBI
|
|
40
|
Huang J, Lyu H, Wang J and Liu B: MicroRNA
regulation and therapeutic targeting of survivin in cancer. Am J
Cancer Res. 5:20–31. 2014.PubMed/NCBI
|
